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Extracorporeal membrane oxygenation (ECMO) is a life saving treatment for patients with severe respiratory failure. We 
present a case of a young child with invasive Panton Valentine leukocidin-producing Staphylococcus aureus infection, 
which is responsible for severe and invasive infection with a high mortality rate, commonly associated with necrotizing 
pneumonia. Our patient presented with septic shock and necrotizing pneumonia leading to severe respiratory failure, refrac-
tory to conventional ventilation means. After 1-day of treatment, venovenous ECMO (VV ECMO) was successfully instituted 
and inotropic support was gradually decreased. Acute renal failure was managed with peritoneal dialysis and intermittent 
venovenous hemofiltration. The patient was weaned from ECMO 9-days later and was mechanically ventilated for another 
3 weeks. Necrotizing pneumonia with pleuropulmonary complications was finally managed by videothoracoscopy with 
evacuation of debris and partial pleural decortication. Osteomyelitis was confirmed by positron emission tomography – 
computed tomography (PET-CT) and was surgically treated. The child was treated with antistaphylococcal antibiotic therapy 
for 54 days. Finally, he was discharged to a rehabilitation center without supplemental oxygen and with his neurologic status 
at his baseline. Our case shows that VV ECMO can be applied to children with severe bacterial pneumonia resistant to 
conventional ventilation strategies and with moderate circulatory failure.
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ation (ECMO) is a life saving treatment 
for patients with severe respiratory 
failure, when conventional means of 
support are inadequate. Furthermore, 
ECMO also protects lungs from ven-
tilator-induced lung injury, commonly 
associated with aggressive mechani-
cal ventilation. (1) Venovenous ECMO 
(VV ECMO) has several advantages 
over venoarterious ECMO (VA ECMO) 
and should be used in the manage-
ment of severe respiratory failure in 
children, when possible. VV ECMO 
could be applied even in respiratory 
failure associated with mild to mod-
erate myocardial dysfunction, since 
cardiac output can be improved with 
adequate oxygenation and lower 
intrathoracic pressures. (1,2) Hypox-
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emic and hypercapnic respiratory fail-
ure can be both successfully managed 
with VV ECMO. The most common 
causes for VV ECMO support in chil-
dren, beside neonates, are viral and 
bacterial pneumonia, acute respiratory 
distress syndrome (ARDS), asthma 
and aspiration of blood, gastric acid 
and foreign substances. (1) 
Recently, the incidence of severe 
infections caused by Staphylococ-
cus aureus has been increasing. This 
increase has been postulated to be due 
to the emergence of strains encoding 
new virulence factors, among which 
Panton Valentine leukocidin (PVL) toxin 
has been most commonly studied. (3) 
PVL is produced by 2% of S. aureus 
isolates and causes white blood cell 
(WBC) lysis and tissue necrosis. (4) 
Case report
A 22-month-old boy, with an unevent-
ful medical history and up to date 
immunization, was admitted to the 
Department of Infectious Diseases, 
at the University Medical Centre Lju-
bljana, because of a two-day history 
of high grade fever (up to 39 °C) and 
painful swelling of the right hip. Ultra-
sound examination revealed effusion 
in the right hip joint, but only a min-
ute amount of serohaemorrhagic fluid 
was evacuated from the joint and sent 
for culturing. Antibiotic treatment with 
cefotaxime and flucloxacillin was start-
ed. Despite supplementation with oxy-
gen, he developed respiratory failure 
and septic shock (respiratory rate 80/
min, oxygen saturation 85–90%, blood 
pressure 70/45 mmHg, heart rate 
190–200/ min, capillary refill time 4–5 
seconds) and hence was transferred 
to the tertiary pediatric intensive care 
unit (PICU) (Department of Pediatric 
Surgery and Intensive Care, University 
Medical Centre Ljubljana).
Immediately after admission (day 0) he 
was intubated and mechanically venti-
lated with pressure-controlled ventila-
tion. Treatment of septic shock was 
continued initially with fluid resuscitation 
(crystalloids). Inotropic support with 
dopamine and vasopressor support 
with norepinephrine was started soon 
after. Norepinephrine was changed to 
epinephrine after 4 hours with addition 
of sodium nitroprusside for the cold 
shock and hydrocortisone was added 
for 7 days. Blood products (red blood 
cells, platelets and fresh frozen plas-
ma) were administered when needed 
according to guidelines. (5) Initial labo-
ratory evaluation revealed: WBC 0.8 
x109/L, CRP 269 mg/L, PCT 209 g/L 
and hemoglobin 104 g/L, lactate 2.2 
mmol/L. Initial arterial blood gas analy-
sis on mechanical ventilation was: pH 
7.15, pCO2 47 mm Hg, PO2 75 mmHg 
(fraction of inspired oxgen,  FiO2 = 
1.0), base excess = -12.4 mmol/L, 
bicarbonate 15.9 mmol/L. Respiratory 
failure was severe, and despite high 
pressure ventilation (peak inspiratory 
pressure (PIP) 42 cm H2O and pos-
itive-end expiratory pressure (PEEP) 
12 cm H2O) a FiO2 1.0 was needed. 
High-frequency oscillatory ventilation 
(HFOV) was started and inhaled nitric 
oxide 20 ppm was added, without 
improvement. Respiratory failure was 
worsening with hypoxemia (arterial 
pO2 56 mmHg; mean airway pres-
sure (MAP) 28; Oxygenation index (OI) 
49.6) and severe hypercapnia (pCO2 
107 mmHg) (figure 1). After 24 hours 
of modulation of respiratory treatment 
we started VV ECMO (QUADROX PLS 
oxygenator, ROTAFLOW centrifugal 
pump; Maquet) (day 1), using 14-Fr 
venous canellas in the right internal 
jugular vein and right common femoral 
vein. PVL-positive methicillin-sensi-
tive S. aureus was grown from blood 
cultures and joint fluid, but not from 
tracheal aspirates. Since the isolate 
was PVL-positive, the antibiotic treat-
ment was changed from flucloxacillin 
to clindamycin and rimfapicin in order 
to minimize toxin production. Acute 
renal failure with oliguria accompany-
ing shock (max creatinine 152 mol/L, 
max urea 45.8 mmol/L) was managed 
with peritoneal dialysis and intermittent 
venovenous hemofiltration. The hemo-
filtration system was added sequen-
tially to the ECMO system. We first 
tried to wean the ECMO on day 8, but 
because of right sided pneumothorax, 
which was successfully drained, it was 
prolonged to day 9. After ECMO wean-
ing and decannulation, the patient 
remained mechanically ventilated on 
different modes of mechanical ventila-
tion for approximately 3 weeks.
Bilateral alveolar infiltrates were seen 
on initial and following chest radio-
graphs and chest computed tomo-
Figure 1. Partial pressure of arte-
rial carbon dioxide (paCO2) and ratio 
of partial pressure of arterial oxy-
gen and fraction of inspired oxygen 
(paO2/FiO2) curves in the patient 
before, during and after  treatment of 
severe respiratory failure with veno-
venous extracorporeal membranous 
oxygenation.
graphic scan on day 16 showed bila-
teral necrotizing pneumonia with abs-
cesses and pneumatocoele formation, 
and persisting pleural effusion with 
a small pneumothorax on the right 
side despite a chest drain (figure 2). 
Streptokinase was applied intrapleu-
rally through the right sided chest drain 
three-times, resulting in improved dra-
inage of the fluid. However, control 
chest computed tomographic scan 
on day 24 showed no improvement 
of lung pathology. Finally, videotho-
racoscopy with evacuation of debris 
from the right plural space and partial 
pleural decortication was performed 
on day 41. Pseudomonas aerugino-
sa was isolated from the evacuated 
debris and the patient was treated with 
ceftazidime for 10 days. After the pro-
cedure, his clinical condition improved 
significantly. 
Because of clinical signs of osteo-
myelitis of the right femur, the boy had 
frequent radiological, ultrasound and 
magnetic resonance (day 12) ima-
gings, but with no discernible signs 
of osteomyelitis. After respiratory and 
hemodynamic stabilization, positron 
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emission tomography – computed 
tomography (PET-CT) was done on 
day 25, which eventually revealed oste-
omyelitis of the right femur. On day 26 
arthrotomy of the right hip with forage 
of the right femur was done. Tissue 
swab, obtained during this procedure, 
was positive for S. aureus eubacteri-
al DNA using the Polymerase chain 
reaction (PCR) method. We continu-
ed with antistaphylococcal antibiotics 
(flucloxacillin/clindamycin alternatively 
with linezolid and rifampicin) for 54 
days altogether. Deep vein thrombosis 
of the right femoral vein, which was 
recognized on day 1, was treated with 
enoxaparin subcutaneously. 
After 51 days of treatment in the inten-
sive care unit, the patient was tran-
sferred to the surgical ward for another 
23 days and then to a rehabilitation 
centre. At that point, he was receiving 
no supplemental oxygen, antibiotic tre-
atment was completed and his neuro-
logic status was at his baseline, apart 
from decreased passive and active 
mobility in the right hip and knee. The 
patient had partial necrosis of the fin-
gertips of the feet and hands, which 
occurred during centralization of the 
blood flow in the first days of septic 
shock.
Discussion
This is the first case of severe pneumo-
nia in a child managed by VV ECMO in 
our institution, which is the only insti-
tution in Slovenia capable of providing 
extracorporeal life support techniques 
in children. (6) Our patient was infected 
with a PVL positive strain of S. aureus 
causing necrotizing pneumonia and 
osteomyelitis leading to respiratory 
and circulatory failure, accompanied 
by acute renal failure. 
ECMO was first used for management 
of term newborns with respiratory fai-
lure (7). Later the indication and pati-
ent selection for this unconventional 
therapy evolved significantly and is 
constantly changing. Today ECMO is 
used for three main distinctive gro-
ups of patients: neonates with respi-
ratory failure refractory to conventional 
management, neonates and children 
with circulatory failure and for children 
with respiratory failure. (1,2,7) Respi-
ratory failure in children was the latest 
indication introduced for ECMO and 
use of ECMO for this group of pati-
ents has increased steadily, leveling 
off in the nineties, but recently it has 
been reported to be slightly increa-
sing again. (2,8) The survival of pedi-
atric respiratory ECMO is 50–55%. (8) 
There are no fixed inclusion criteria 
for pediatric respiratory ECMO, and 
ECMO is usually started if there is a 
high probability of a lethal outcome 
despite maximal conventional therapy. 
Lung disease should be considered 
to be reversible; the patient should be 
mechanically ventilated for less than 
14 days; and no other organs major 
complications (significant neurologic 
morbidity, ongoing hemorrhagic con-
dition, or multiple organ system failu-
re) should be present when starting 
ECMO. (1,7,8). Unlike neonates, OI is 
not as predictive for ECMO use in chil-
dren and is not tightly used for guiding 
the indications for pediatric respiratory 
ECMO. (7) In our patient the etiology 
of respiratory failure was potentially 
reversible; he was mechanically venti-
lated for only 24 hours; he had profo-
und hypercarbia; his OI was more than 
40; and his paO2/FiO2 ratio was less 
than 75 mmHg. When we decided to 
start ECMO, we considered that there 
was a high probability of death with 
conventional support. Therefore, the 
majority of proposed inclusion criteria 
for pediatric respiratory ECMO, which 
are sometimes used, (7,8) were met in 
our patient. 
Community-acquired infections with 
PVL toxin producing S. aureus are rare, 
but often invasive and associated with 
toxic shock-like illness, necrotizing 
pneumonia with complications (pne-
umatocoeles, recurrent pneumotho-
races, pleural effusion, empyema and 
lung abscesses), and osteoarticular 
infections with venous thrombosis (3,9-
13) as in our patient. There are some 
reports of fatal outcomes in infections 
with S. aureus in children, although the 
presence of PVL toxin was not usually 
investigated. (14,15) In the seminal 
article by Gillet et al. the case fatali-
ty rate of patients with PVL-positive 
staphylococcal pneumonia was 75%. 
(16) Children infected by PVL-positi-
ve S. aureus usually die because of 
respiratory or combined respiratory 
and circulatory failure. (14,15) ECMO 
presents a possibility to change the 
outcome in life-threatening cases and 
ECMO use is increasingly reported in 
children infected with S. aureus. (17) 
Stroud et al. recently described two 
children infected by PVL-positive S. 
aureus, who were successfully sup-
ported with VA ECMO. (3) We decided 
for VV ECMO despite circulatory failure 
in our patient, since he was stabilized 
on the first day with inotropic support. 
Furthermore, there are several advan-
tages of VV ECMO compared to VA 
ECMO: prepulmonary oxygenation 
with elevation of mixed venous satu-
ration and diminishing the effect of 
intrapulmonary shunts, sparing of the 
carotid artery, maintaining full pulsa-
tile blood flow, trapping of potential 
emboli in the pulmonary vascular bed 
and ability of percutaneus cannulation, 
although in our patient the cannulation 
was surgical. (1,18) Our decision to 
start VV ECMO proved to be correct, 
since after the institution of VV ECMO 
we could gradually lower the inotropes, 
although no direct cardiac support 
was delivered by VV ECMO. In adults 
Figure 2. Chest computed tomo-
graphy scan showing bilateral lung 
disease with abscesses and pne-
umatocoeles and pleural effusion 
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VV ECMO is usually used in cases of 
severe respiratory failure caused by 
PVL-positive S. aureus. (19)
In conclusion, VV ECMO is successful 
unconventional respiratory support in 
children with respiratory failure due to 
different etiologies. Our case shows 
that VV ECMO can be applied for chil-
dren with severe bacterial pneumonia 
resistant to conventional ventilation 
strategies with moderate circulatory 
failure.
